Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (10.5 & 10.16.19)

May 10, 2019
By: Julie Poucher Harbin, Writer, DCI

Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R01, R21)
Funding Agency: 
National Institutes of Health

This Funding Opportunity Announcement (FOA) encourages collaborative applications that will contribute to the identification and characterization of patients at risk of developing cancer treatment-related cardiotoxicity. The primary intent is to mitigate cardiovascular dysfunction while optimizing cancer outcomes. To accomplish this, methods that evaluate cardiovascular risk prior to treatment and integrate evidence-based cancer treatment regimens with cardiovascular screening, diagnostic, and/or management strategies are sought. Research applications should focus on mitigation/management of adverse effects associated with anti-cancer treatments including: cytotoxic chemotherapies, targeted agents, immunomodulatory therapies and radiation (that occur during cancer treatment and/or long-term survivorship) as defined by cardiac and/or vascular specific common terminology criteria for adverse events (CTCAE).

This FOA runs in parallel with an FOA of identical scientific scope, PA-19-111, which utilizes the Exploratory/Developmental Grant (R21) mechanism to support investigation of novel scientific ideas or new model systems, tools or technologies that have the potential for significant impact on biomedical or biobehavioral research.

Application Deadlines: 

  •     R01 Due Dates: Feb. 5, Jun. 5, Oct. 5
  •     R21 Due Dates: Feb. 16, Jun. 16, Oct. 16

Eligibility: Faculty 

For more Information: